Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials

Chronic graft-versus-host disease (cGVHD) of the lung, or bronchiolitis obliterans syndrome (BOS), is a high-risk disease manifestation associated with poor outcomes. Currently available treatments have demonstrated limited clinical efficacy in this setting. Belumosudil is a novel oral selective rho...

Descripción completa

Detalles Bibliográficos
Autores principales: DeFilipp, Zachariah, Kim, Haesook T., Yang, Zhongming, Noonan, John, Blazar, Bruce R., Lee, Stephanie J., Pavletic, Steven Z., Cutler, Corey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792394/
https://www.ncbi.nlm.nih.gov/pubmed/36083121
http://dx.doi.org/10.1182/bloodadvances.2022008095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792394/
https://www.ncbi.nlm.nih.gov/pubmed/36083121
http://dx.doi.org/10.1182/bloodadvances.2022008095

Ejemplares similares